We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00674700
Recruitment Status : Completed
First Posted : May 8, 2008
Results First Posted : May 19, 2016
Last Update Posted : May 19, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic rhinitis symptoms and rescue medication usage

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: 300 IR house dust mites allergen extract tablet Drug: 500 IR house dust mites allergen extract tablet Drug: Placebo tablet Phase 2 Phase 3

Detailed Description:

Allergic rhinitis is a high-prevalence disease in many developed countries, affecting about 10 to 20% of the general population. House dust mite allergens are known to cause perennial allergic rhinitis.

In designing the present study, the guidelines proposed by the World Allergy Organization (WAO) task force for methodology of immunotherapy studies have been taken into consideration.

After a 2-month screening period, patients will be administered the dose of 300 IR- or 500 IR-house dust mite allergen-based tablets or placebo for a period of 12 months. The carry-over effect will be evaluated after a treatment-free follow up period of 12 months.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 509 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, DBPC, Multi-national Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis
Study Start Date : October 2007
Primary Completion Date : February 2009
Study Completion Date : February 2010
Arms and Interventions

Arm Intervention/treatment
Active Comparator: 300 IR
300 IR house dust mites allergen extract tablet
Drug: 300 IR house dust mites allergen extract tablet
One sublingual tablet daily for one year
Other Name: Sublingual immunotherapy tablet
Active Comparator: 500 IR
500 IR house dust mites allergen extract tablet
Drug: 500 IR house dust mites allergen extract tablet
One sublingual tablet daily for one year
Other Name: Sublingual immunotherapy tablet
Placebo Comparator: Placebo
Placebo tablet
Drug: Placebo tablet
One sublingual tablet daily for one year
Other Name: Sublingual placebo tablet


Outcome Measures

Primary Outcome Measures :
  1. Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period [ Time Frame: Last 3 months of Year 1 ]

    The AAdSS is derived from the daily Rhinoconjunctivitis Total Symptom Scores (RTSS), based on the severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion, each graded on a 4-point scale (0-3; 0: absent, 1: mild, 2: moderate, 3: severe).

    It ranges from 0 to 12, the higher the score the more severe the rhinitis.



Secondary Outcome Measures :
  1. Average Rhinitis Total Symptom Score (ARTSS) [ Time Frame: Last 3 months of Year 1 ]
    The Rhinitis Total Symptom Score (RTSS) evaluates the presence and severity of the 4 rhinitis symptoms: sneezing, rhinorrhoea, nasal pruritus and nasal congestion (absence of symptom (0), mild symptom (1), moderate symptom (2), severe symptom (3)). It ranges from 0 to 12, the higher the score the more severe the rhinitis.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female outpatients aged 18 to 50 years (inclusive).
  2. Patients who have been informed of the nature and aims of the study and have given their written consent
  3. Patients must be in general good health as determined by past medical history, physical examination and safety laboratory tests.
  4. Female patients of childbearing potential are eligible
  5. Negative urine pregnancy test on female patients of childbearing potential.
  6. House dust mite-related allergic rhinitis for at least 1 year.
  7. Sensitised to D. pteronyssinus or D. farinae (positive SPT with wheal diameter greater than 3 mm and a specific IgE level ≥ 0.7 kU/L).
  8. Baseline ARTSS > 5 (after completion of the 7-day daily record card).
  9. Patients who are willing to comply with the protocol.
  10. Patients who are able to understand the information given and the text of the consent form, and who are able to complete the daily record card and the RQLQ.

Exclusion Criteria:

  1. Whatever the considered allergens, co-sensitisation leading to clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites).
  2. Patients with any nasal condition that could confound the efficacy or safety assessments (for example nasal polyposis).
  3. Patients sensitised to cat or dog allergens and living with these animals at home.
  4. Pregnant, breast-feeding / lactating or sexually active women of childbearing potential who are not using a medically accepted contraceptive method.
  5. Asthma requiring treatment other than beta-2 inhaled agonists. Patients with intermittent asthma not necessitating inhaled or systemic corticoid treatment may be included (corresponding to the Global Initiative for Asthma [GINA] Step 1).
  6. Patients treated with systemic, nasal or inhaled steroids (whatever the indication) within 4 weeks before Visit 1.
  7. Patients treated with long acting systemic steroids (whatever the indication) within 12 weeks before Visit 1 and before Visit 2.
  8. FEV1 < 80% of predicted value at Visit 1.
  9. Patients who received allergy specific immunotherapy for house dust mites in the last 10 years.
  10. Patients at risk of non-compliance.
  11. Participation in any clinical study within the 12 weeks before Visit 1.
  12. Investigators, co-investigators, as well as their children or spouses and all the study collaborators should not be enrolled in the study.
  13. Any change in environmental measures for allergen avoidance during the study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00674700


Sponsors and Collaborators
Stallergenes Greer
Investigators
Study Chair: Karl-Christian BERGMANN, MD Allergie-Centrum-Charité / ECARF
More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Stallergenes Greer
ClinicalTrials.gov Identifier: NCT00674700     History of Changes
Other Study ID Numbers: VO57.07
First Posted: May 8, 2008    Key Record Dates
Results First Posted: May 19, 2016
Last Update Posted: May 19, 2016
Last Verified: April 2016

Keywords provided by Stallergenes Greer:
House dust mites allergy

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases